[1]
|
Sung, H., Ferlay, J., Siegel, R.L., et al. (2021) Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians, 71, 209-249.
https://doi.org/10.3322/caac.21660
|
[2]
|
Feng, R.-M., Zong, Y.-N., Cao, S.-M., et al. (2019) Current Cancer Situation in China: Good or Bad News from the 2018 Global Cancer Statistics? Cancer Communications (London, England), 39, 22.
https://doi.org/10.1186/s40880-019-0368-6
|
[3]
|
Lin, T.-Y., Lee, C.-S., Chen, K.-M., et al. (1987) Role of Surgery in the Treatment of Primary Carcinoma of the Liver: A 31-Year Experience. British Journal of Surgery, 74, 839-842. https://doi.org/10.1002/bjs.1800740931
|
[4]
|
Yamashita, T. (2012) Current Status of Hepatocellular Carcinoma Treatment in Japan: Hepatic Arterial Infusion Chemotherapy. Clinical Drug Investigation, 32, 15-23. https://doi.org/10.1007/BF03265493
|
[5]
|
石明, 何敏柯, 陈敏山. 肝动脉灌注化疗的现状与前景[J]. 外科理论与实践, 2020, 25(1): 10-14.
|
[6]
|
Zwelling, L.A., Michaels, S., Schwartz, H., et al. (1981) DNA Cross-Linking as an Indicator of Sensitivity and Resistance of Mouse L1210 Leukemia to Cis-diamminedichloroplatinum(II) and L-phenylalanine Mustard. Cancer Research, 41, 640-649.
|
[7]
|
Kondo, M., Morimoto, M., Ishii, T., et al. (2015) Hepatic Arterial Infusion Chemotherapy with Cisplatin and Sorafenib in Hepatocellular Carcinoma Patients Unresponsive to Transarterial Chemoembolization: A Propensity Score-Based Weighting. Journal of Digestive Diseases, 16, 143-151. https://doi.org/10.1111/1751-2980.12221
|
[8]
|
Takaki, H., Yamakado, K., Tsurusaki, M., et al. (2015) Hepatic Arterial Infusion Chemotherapy with Fine-Powder Cisplatin and Iodized-Oil Suspension in Patients with Intermediate-Stage and Advanced-Stage (Barcelona Clinic Liver Cancer Stage-B or Stage-C) Hepatocellular Carcinoma: Multicenter Phase-II Clinical Study. International Journal of Clinical Oncology, 20, 745-754. https://doi.org/10.1007/s10147-014-0773-4
|
[9]
|
Qin, S.K., Bai, Y.X., Lim, H.Y., et al. (2013) Randomized, Multicenter, Open-Label Study of Oxaliplatin plus Fluorouracil/Leucovorin versus Doxorubicin as Palliative Chemotherapy in Patients with Advanced Hepatocellular Carcinoma from Asia. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, 31, 3501-3508. https://doi.org/10.1200/JCO.2012.44.5643
|
[10]
|
李伟, 张良杰, 李冬冬, 等. 奥沙利铂联合氟尿嘧啶/亚叶酸钙方案经肝动脉灌注化疗治疗晚期肝细胞癌[J]. 泰山医学院学报, 2021, 42(1): 37-40.
|
[11]
|
He, M.-K., Le, Y., Li, Q.-J., et al. (2017) Hepatic Artery Infusion Chemotherapy Using mFOLFOX versus Transarterial Chemoembolization for Massive Unresectable Hepatocellular Carcinoma: A Prospective Non-Randomized Study. Chinese Journal of Cancer, 36, 704-711. https://doi.org/10.1186/s40880-017-0251-2
|
[12]
|
Lyu, N., Lin, Y., Kong, Y., et al. (2018) FOXAI: A Phase II Trial Evaluating the Efficacy and Safety of Hepatic Arterial Infusion of Oxaliplatin plus Fluorouracil/Leucovorin for Advanced Hepatocellular Carcinoma. Gut, 67, 395-396.
https://doi.org/10.1136/gutjnl-2017-314138
|
[13]
|
吕会来, 张丽, 温士旺, 等. 雷替曲塞联合奥沙利铂二线治疗晚期贲门癌的疗效观察[J]. 河北医科大学学报, 2016, 37(1): 24-26.
|
[14]
|
Wu, D.-M., Wang, Y.-J., Fan, S.-H., et al. (2017) Network Meta-Analysis of the Efficacy of First-Line Chemotherapy Regimens in Patients with Advanced Colorectal Cancer. Oncotarget, 8, 100668-100677.
https://doi.org/10.18632/oncotarget.22177
|
[15]
|
Liu, B.J., Zhu, X., Gao, S., et al. (2019) Safety and Efficacy of Hepatic Arterial Infusion Chemotherapy with Raltitrexed and Oxaliplatin Post-Transarterial Chemoembolization for Unresectable Hepatocellular Carcinoma. Journal of Interventional Medicine, 2, 91-96. https://doi.org/10.1016/j.jimed.2019.07.006
|
[16]
|
Guo, J.-H., Zhang, H.-Y., Gao, S., et al. (2017) Hepatic Artery Infusion with Raltitrexed or 5-Fluorouracil for Colorectal Cancer Liver Metastasis. World Journal of Gastroenterology, 23, 1406-1411.
https://doi.org/10.3748/wjg.v23.i8.1406
|
[17]
|
艾宁, 李智岗, 王永中, 等. 雷替曲塞联合洛铂动脉灌注方案在原发性肝癌介入中的应用价值[J]. 河北医科大学学报, 2019, 40(12): 1430-1432+1454.
|
[18]
|
Nagamatsu, H., Sumie, S., Niizeki, T., et al. (2016) Hepatic Arterial Infusion Chemoembolization Therapy for Advanced Hepatocellular Carcinoma: Multicenter Phase II Study. Cancer Chemotherapy and Pharmacology, 77, 243-250.
https://doi.org/10.1007/s00280-015-2892-7
|
[19]
|
Kasai, K., Ushio, A., Kasai, Y., et al. (2011) Combination Therapy of Intra-Arterial 5-Fluorouracil and Systemic Pegylated Interferon α-2b for Advanced Hepatocellular Carcinoma. International Journal of Clinical Oncology, 16, 221-229. https://doi.org/10.1007/s10147-010-0151-9
|
[20]
|
Kasai, K., Kooka, Y., Suzuki, Y., et al. (2014) Efficacy of Hepatic Arterial Infusion Chemotherapy Using 5-Fluorouracil and Systemic Pegylated Interferon α-2b for Advanced Intrahepatic Cholangiocarcinoma. Annals of Surgical Oncology, 21, 3638-3645. https://doi.org/10.1245/s10434-014-3766-7
|
[21]
|
Nouso, K., Miyahara, K., Uchida, D., et al. (2013) Effect of Hepatic Arterial Infusion Chemotherapy of 5-Fluorouracil and Cisplatin for Advanced Hepatocellular Carcinoma in the Nationwide Survey of Primary Liver Cancer in Japan. British Journal of Cancer, 109, 1904-1907. https://doi.org/10.1038/bjc.2013.542
|
[22]
|
Obi, S., Sato, S. and Kawai, T. (2015) Current Status of Hepatic Arterial Infusion Chemotherapy. Liver Cancer, 4, 188-199. https://doi.org/10.1159/000367746
|
[23]
|
Kudo, M. (2012) Treatment of Advanced Hepatocellular Carcinoma with Emphasis on Hepatic Arterial Infusion Chemotherapy and Molecular Targeted Therapy. Liver Cancer, 1, 62-70. https://doi.org/10.1159/000342402
|
[24]
|
Wilhelm, S.M., Carter, C., Tang, L., et al. (2004) BAY 43-9006 Exhibits Broad Spectrum Oral Antitumor Activity and Targets the RAF/MEK/ERK Pathway and Receptor Tyrosine Kinases Involved in Tumor Progression and Angiogenesis. Cancer Research, 64, 7099-7109. https://doi.org/10.1158/0008-5472.CAN-04-1443
|
[25]
|
Llovet, J.M., Di Bisceglie Adrian, M., Bruix, J., et al. (2008) Design and Endpoints of Clinical Trials in Hepatocellular Carcinoma. Journal of the National Cancer Institute, 100, 698-711. https://doi.org/10.1093/jnci/djn134
|
[26]
|
He, M.K., Li, Q.J., Zou, R.H., et al. (2019) Sorafenib plus Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin vs Sorafenib Alone for Hepatocellular Carcinoma with Portal Vein Invasion: A Randomized Clinical Trial. JAMA Oncology, 5, 953-960. https://doi.org/10.1001/jamaoncol.2019.0250
|
[27]
|
Nagai, H., Mukozu, T., Ogino, Y.U., et al. (2015) Sorafenib and Hepatic Arterial Infusion Chemotherapy for Advanced Hepatocellular Carcinoma with Portal Vein Tumor Thrombus. Anticancer Research, 35, 2269-2278.
|
[28]
|
Hato, T., Goyal, L., Greten, T.F., et al. (2014) Immune Checkpoint Blockade in Hepatocellular Carcinoma: Current Progress and Future Directions. Hepatology (Baltimore, Md.), 60, 1776-1782. https://doi.org/10.1002/hep.27246
|
[29]
|
Johnston, M.P. and Khakoo, S.I. (2019) Immunotherapy for Hepatocellular Carcinoma: Current and Future. World Journal of Gastroenterology, 25, 2977-2989. https://doi.org/10.3748/wjg.v25.i24.2977
|
[30]
|
Mei, J., Tang, Y.H., Wei, W., et al. (2021) Hepatic Arterial Infusion Chemotherapy Combined with PD-1 Inhibitors Plus Lenvatinib versus PD-1 Inhibitors Plus Lenvatinib for Advanced Hepatocellular Carcinoma. Frontiers in Oncology, 11, Article ID: 618206. https://doi.org/10.3389/fonc.2021.618206
|
[31]
|
Mei, J., Li, S.H., Li, Q.J., et al. (2021) Anti-PD-1 Immunotherapy Improves the Efficacy of Hepatic Artery Infusion Chemotherapy in Advanced Hepatocellular Carcinoma. Journal of Hepatocellular Carcinoma, 8, 167-176.
https://doi.org/10.2147/JHC.S298538
|